ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.

Saved in:
Bibliographic Details
Title: ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Authors: Maithel SK; Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA. smaithe@emory.edu.
Source: Annals of surgical oncology [Ann Surg Oncol] 2023 Oct; Vol. 30 (11), pp. 6567-6568. Date of Electronic Publication: 2023 Jun 29.
Publication Type: Journal Article; Comment
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1534-4681
DOI:10.1245/s10434-023-13811-x